5:54 PM
Mar 08, 2013
 |  BC Extra  |  Company News

FMC wants new Vivus board, strategy

Vivus Inc. (NASDAQ:VVUS) investor First Manhattan Co. (FMC) said it plans to nominate a slate of six new directors to the biotech's board and urged Vivus to find a U.S. partner for obesity drug Qsymia phentermine/topiramate. In a letter to CEO Leland Wilson, FMC said the "commercial planning and execution for Qsymia has proven to be deeply flawed," and that the biotech...

Read the full 297 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >